The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status by Glajcar, Anna et al.
ORIGINAL ARTICLE
The composition of T cell infiltrates varies in primary invasive
breast cancer of different molecular subtypes as well as according
to tumor size and nodal status
Anna Glajcar1 & Joanna Szpor1 & Diana Hodorowicz-Zaniewska2 & Katarzyna Ewa Tyrak3 & Krzysztof Okoń1
Received: 8 January 2019 /Revised: 6 March 2019 /Accepted: 26 March 2019 /Published online: 17 April 2019
# The Author(s) 2019
Abstract
T lymphocytes are the most numerous immune cells in tumor-associated infiltrates and include several subpopulations of either
anticancer or pro-tumorigenic functions. However, the associations between levels of different T cell subsets and breast cancer
molecular subtypes as well as other prognostic factors have not been fully established yet. We performed immunohistochemistry
for CD8 (cytotoxic T cells (CTL)), FOXP3 (regulatory T cells (Tregs)), and GATA3 (Th2 cells) in 106 formalin-fixed paraffin-
embedded invasive breast cancer tissue samples and analyzed both the numbers and percentages of investigated cells in tumor-
associated infiltrates. We observed that triple-negative breast cancer (TNBC) and HER2+ non-luminal breast tumors were
associated with more numerous CTLs and Tregs and a higher Treg/Th2 cell ratio as compared with luminal A subtype. A higher
Treg percentage was related to a decreased hormone receptor expression, an increase in the Ki67 level, a greater tumor size of
luminal tumors, and the presence of lymph node metastases. Moreover, differences in the composition of T cell infiltrates were
associated with HER2 status and histologic grade and type, and a distinct immune pattern was observed in tumors of different
phenotypes regarding pTstage and nodal status. The results of our work show the diversity of Tcell infiltrates in primary invasive
breast cancers of different phenotypes and suggest that progression of luminal or non-luminal tumors is related to distinct tumor-
associated T cell composition.
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Introduction
In tumor microenvironment, lymphocytes predominate in
mononuclear infiltrates and represent an adaptive antitumor
immune response. The most abundant population of tumor-
associated lymphocytes is T cells, which include many
subpopulations differing in their function. Among them,
CD8+ cytotoxic T lymphocytes (CTLs) are particularly
known for their cytolytic activity against cancer cells. On the
contrary, GATA3+ T helper 2 (Th2) cells and FOXP3+ regu-
latory T lymphocytes (Tregs) downregulate antitumor im-
mune response by impairing antigen presentation, activity,
and cytotoxicity of other immune cells, thus promoting tumor
growth and immune tolerance. Tregs originate from naïve T
cells both in the thymus and at the periphery, and the process
of their differentiation is orchestrated by a specific cytokine
milieu. Molecules secreted by tumor-infiltrating lymphocytes
(TILs), cancer cells, and other components of tumor microen-
vironment affect the composition and function of the cancer
milieu, and, thereby, modulate the course of breast cancer
progression [1–6]. It was observed that TILs rich in Tregs
interact with cancer-associated fibroblasts, contributing to
stromal remodeling, that presumably promote tumor growth
and invasion [7]. The density of T cells was reported to in-
crease as mammary tumor progresses from normal breast tis-
sue, through benign and in situ lesions, to invasive ductal
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cancers; this finding was interpreted as a stepwise increase in
immunity with the course of mammary tumorigenesis [5–8].
An antitumoral immunity shows plasticity (immunoediting)
and changes in time from tumor elimination (based highly
on CTLs), through the equilibrium phase to immune escape
(characterized by immunosuppressive profile of tumor micro-
environment and generation of Tregs). The process of
immunoediting is thought to result from the shifted balance
between respective T cell phenotypes and selection of non-
immunogenic clones [9, 10]. In line with these, the immune
response appears to be dysfunctional and skewed toward sup-
pression in invasive breast tumor tissue [2, 11].
Since the discovery of the intrinsic molecular subtypes that
differ in their genetic pattern and clinical aggressiveness, in-
vasive breast cancer has become regarded as a heterogeneous
disease [12, 13]. To a certain extent, the interplay between
malignant breast tumor and TILs is dependent on tumor ge-
netics and biology [10]. Moreover, there is growing evidence
that prognostic and predictive relevance of TILs varies in
breast cancer of different intrinsic subtypes [1, 4, 5, 10, 11].
Nonetheless, the relationships between composition of lym-
phocytic milieus and breast cancer molecular subtypes have
not been fully elucidated so far. Relationships between cancer
and its microenvironment are of great interest, as some che-
motherapeutic agents may elicit or enhance antitumor immune
reactions, and innate, adaptive, cellular, and humoral path-
ways may be involved in cancer cell killing [14].
Simultaneously, new therapeutic approaches that aim at induc-
ing potent immune response are sought. This includes an in-
crease of tumor immunogenicity, inhibition of immune eva-
sion [10, 11], and enhancement of cytotoxic and Th1 re-
sponse, as well as a reduction of regulatory and Th2 cell im-
pact on neoplastic breast tissue [5].
In our study, we investigated the lymphocyte infiltrate
composition in order to assess its relationships with invasive
breast cancer molecular subtypes and the occurrence of other
prognostic and predictive markers for this disease. For this
purpose, we evaluated both numbers of CTLs, Tregs, and
Th2 cells and their percentages in tumor-associated immune
infiltrates. Moreover, we also calculated proportions of inves-
tigated cells to assess differences in their relative quantities
with regard to clinico-pathological indicators in breast cancer.
Material and methods
Material
The material comprised 106 routinely processed, formalin-
fixed paraffin-embedded tissues of primary invasive breast
carcinomas diagnosed between 2002 and 2015. The patients
who received presurgical chemotherapy were excluded from
the study. The archival hematoxylin-eosin–stained slides were
re-evaluated and representative, well-preserved specimens
were chosen for immunohistochemistry. The Nottingham
Histologic Grade system was used for grading, and the 8th
edition of the AJCC system was used for staging [15].
Immunohistochemistry
Immunohistochemistry (IHC) for CD8, FOXP3, GATA3,
estrogen receptor (ER), progesterone receptor (PR), and
Ki67 protein was performed according to the protocol
routinely used in our laboratory. The selected blocks were
cut into 4-μm-thick sections. Antigen retrieval was per-
formed by incubating the slides in a citrate buffer (pH 6.0;
0.01 M) or EDTA (pH 8.0; 0.01 M) at 97 °C in a water
bath for 40 and 30 min, respectively. The UltraVision
Quanto Detection system (Lab Vision, Thermo Fisher
Scientific, USA) and 3,3′-diaminobenzidine as chromogen
were used, and the slides were counterstained with Mayer
hematoxylin (Thermo Fisher Scientific, Waltham, USA)
and coverslipped. Immunohistochemistry for HER2
(PATHWAY 4B5, Ventana Medical Systems Inc., USA)
was performed on a BenchMark BMK Classic autostainer
(Ventana, USA) using an UltraView DAB Detection Kit
(Ventana Medical Systems Inc., USA). The primary anti-
bodies used are listed in Table 1.
For specimens with HER2 status 2+ in immunohistochem-
istry, fluorescence in situ hybridization (FISH)was conducted.
FISH was performed using a PathVysion HER-2 DNA Probe
Kit II (Abbott Molecular, USA) according to the manufac-
turer’s protocol. The red Locus Specific Identifier (LSI)
HER-2/neu and green Centromere Enumeration Probe (CEP
17) signals were counted on a fluorescence microscope
equipped with specific filter sets and HER-2/neu to CEP17
ratio > 2.0 was considered as HER2/neu amplification [16].
Evaluation of immunostaining and lymphocytic
infiltrates
The immunostained slides were initially scanned on a
Nikon Labophot-2 optical microscope (Tokyo, Japan) at
low magnification (× 100), and the areas with the highest
number of positive cells were chosen. Then, for CD8+
and FOXP3+ T cell populations, positively stained cells
were counted in 5 high-power fields (HPFs; × 400, 0.2-
mm2 field area) and added together, which represented
cell counts in 1 mm2 of the examined tissue. The positive
cells located in tumor-surrounding stroma, no further than
1 HPF from the tumor edge, were regarded as invasive
margin or tumor edge, while positive cells located within
neoplastic tissue (i.e., in contact with cancer cells) were
considered intratumoral or intraepithelial population
(Fig. 1). Additionally, for CD8+, FOXP3+, and GATA3+
cells, the percentages of positively stained cells were
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visually evaluated in mononuclear infiltrate at the inva-
sion front. The percentages of investigated cells were
evaluated in 5 HPFs and averaged. Finally, the ratios of
examined T cell populations were calculated separately
for their numbers in the intratumoral area and at the tumor
edge, as well as for their percentages in tumor-
surrounding stroma. In the study, CD8+, FOXP3+, and
GATA3+ were considered CTLs, Tregs, and Th2 cells,
respectively.
Additionally, evaluation of TILs was performed in tu-
mor stroma, in the whole tissue section, according to the
recommendations of the International TILs Working
Group 2014 [17].
Positive ER and PR expression thresholds were set when ≥
1% of neoplastic cells showed positive immunostaining. The
threshold for discriminating between low and high Ki67 ex-
pression was set at ≥ 20% of positive cells. Scoring of the
HER2 staining was performed by the standard method [16].
Definition of breast cancer molecular subtypes
The cases were classified into molecular subtypes according
to the St Gallen 2015 International Expert Consensus [13]:
luminal A (ER+ and PR ≥ 20%, Ki67 < 20%, HER2−), lumi-
nal B/HER2− (ER+, HER2− with PR <20% and/or Ki67 ≥
20%), luminal B/HER2+ (ER+ or PR+, HER2+), HER2+
non-luminal (ER−/PR−/HER2+), and triple-negative breast
cancer (ER−/PR−/HER2−).
Statistical analysis
To assess the differences between groups, the ANOVA
Kruskal–Wallis and Mann–Whitney U tests were performed.
A t test was applied for normally distributed variables. The
correlations between groups were evaluated by using the
Spearman rank test. All analyses were performed using
Statistica 13 (StatSoft Inc., USA). In brackets, the data are
expressed as mean values ± standard deviations; p values <
0.05 were considered statistically significant.
Results
A detailed description of the study group is shown in Table 2.
Lymphocyte infiltrate composition in different breast
cancer molecular subtypes
We noted that both TNBC and HER2+ non-luminal tumors
were more abundantly infiltrated by lymphocytes, as seen on
H&E sections, in comparison with luminal A lesions
(p < 0.001). Moreover, the HER2+ non-luminal subtype was
also associated with a higher TIL level than lesions of luminal
B phenotype (p < 0.007). With reference to the numbers of
individual lymphocyte populations, we observed significantly
more CTLs at the invasive margin of TNBC and HER2+ non-
luminal cancers than in luminal A tumors (p < 0.001 for both
Fig. 1 Representative infiltration of T cell subpopulations in investigated invasive breast cancer tissues; a CTLs, b Tregs, c Th2 cell infiltrates (at
invasive margin); immunostaining for CD8, FOXP3, and GATA3, respectively; light microscopy, magnification used: × 200 (a, b) and × 400 (c)
Table 1 Antibodies used in the study
Clone Dilution Antigen retrieval Incubation time Manufacturer
CD8 C8/144B 1:100 Citrate 60 min Dako, USA
FOXP3 236A/E7 1:100 EDTA 30 min Abcam, UK
GATA
3
L50–823 1:100 EDTA 30 min Cell Marque, USA
ER 6F11 1:100 Citrate 30 min Novocastra (Leica Biosystems, Germany)
PR PgR636 1:100 Citrate 60 min Dako, USA
Ki67 MIB-1 1:100 Citrate 30 min Dako, USA
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comparisons). The same observation was made for Tregs of the
tumor edge (TNBC vs. luminal A: p < 0.006; HER2+ non-
luminal vs luminal A: p < 0.001), and this population was more
abundant in luminal B cancers, as compared with luminal A
tumors (p < 0.050). The intratumoral Treg level was also sig-
nificantly higher in TNBC than in luminal A tumors
(p < 0.003). No statistically significant differences were ob-
served for CTL/Treg number ratio both within neoplastic epi-
thelium and at the invasive margin (Fig. 2, Tables 3 and 4).
Regarding the percentages of analyzed T cell populations in
tumor-associated infiltrates, we observed higher Treg/Th2 cell
percentage ratio at the tumor edge of HER2+ non-luminal as
compared with luminal A lesions (p < 0.040; Fig. 2, Table 4).
According to St Gallen 2015 distinction between luminal A
and B molecular subtypes, the latter was characterized by
higher numbers of CTLs (723.2 ± 406.4 vs. 445.8 ± 303.6,
p < 0.025) and Tregs (252.2 ± 140.9 vs. 127.0 ± 110.8,
p < 0.005) located at the invasive margin of a tumor.
As far as the HER2 status was concerned, we found that
more abundant TILs as well as more numerous CTLs and
Tregs at the invasion front were associated with HER2 over-
expression (p < 0.001, p < 0.010, and p < 0.001, respectively;
Tables 3 and 4).
The expression of hormone receptors showed a negative
correlation with CTL counts at the tumor edge (ER: R = −
0.46, PR: − 0.47, p < 0.001), intratumoral and invasive margin
Treg numbers (ER: R = − 0.26, p < 0.008 and R = − 0.44,
p < 0.001; PR: R = − 0.26, p < 0.007 and R = − 0.45,
p < 0.001 respectively), the percentage of Tregs at tumor edge
(ER: not significant, PR: R = − 0.21, p < 0.035), TIL level
(ER: R = − 0.57, PR: R = − 0.54, p < 0.001), and the Treg/
Th2 cell percentage ratio (ER: R = − 0.34, p < 0.002; PR:
R = − 0.31 p < 0.001) as well as a positive correlation with
both Th2 cell percentage (ER: R = 0.25, p < 0.015; PR: R =
0.19, p < 0.050) and CTL/Th2 cell percentage ratio (ER: R =
0.21, p < 0.035; PR: R = 0.22, p < 0.030) at tumor edge.
Expression of Ki67 in neoplastic cells correlated positively
with CTL and Treg counts both within tumor and at the inva-
sive margin (CTLs: R = 0.28, p < 0.005 and R = 0.41,
p < 0.001; Tregs: R = 0.42 and R = 0.38, p < 0.001, respective-
ly), Treg percentage at invasion front (R = 0.27, p < 0.007),
TIL infiltrate (R = 0.46, p < 0.001), and Treg/Th2 cell percent-
age ratio (R = 0.29, p < 0.004).
The relationships between lymphocyte infiltrate
composition and other prognostic indicators in breast
cancer
With regard to the tumor size, we stratified the analyzed sam-
ples into small tumors (pT1) and the lesions of diameter great-
er than 2 cm (pT > 1). We observed that the latter was charac-
terized by more abundant TIL infiltrates (33.6 ± 20.7 vs. 23.8
± 18.2, p < 0.007), higher intratumoral CTL number (172.7 ±
146.8 vs. 131.3 ± 179.9, p < 0.007), and higher Treg/Th2 cell
percentage ratio at the invasion front (0.25 ± 0.12 vs. 0.22 ±
0.18, p < 0.045). When cancers of different phenotypes were
analyzed separately, in cases of luminal cancers, a greater
tumor diameter was associated with more numerous
intratumoral CTLs (90.2 ± 67.0 vs. 170.1 ± 123.0, p < 0.006)
and Tregs (35.9 ± 39.8 vs. 66.5 ± 57.9, p < 0.010), higher Treg
percentage at the tumor edge (8.9 ± 4.1 vs. 11.2 ± 4.1,
p < 0.020), TIL level (16.4 ± 14.8 vs. 26.4 ± 18.4, p < 0.025),
and Treg/Th2 cell percentage ratio at invasive margin (0.18 ±
0.12 vs. 0.23 ± 0.09, p < 0.015). No significant differences
were observed between the composition of lymphocytic infil-
trate and tumor size in the non-luminal group.
Primary breast cancers that developed nodal metastases
showed more prominent TILs (32.9 ± 19.3 vs. 24.6 ± 19.7,
Table 2 Characteristics of the study group
Characteristic No. of cases Percentage
Total 106 100.0
Mean patient age 55.7 (range 29–87)
Tumor size
pT1 56 52.8
pT2 46 43.4
pT3 3 2.8
pT4 1 0.9
Nodal involvement
pN0 53 50.0
pN1 32 30.2
pN2 8 7.5
pN3 12 11.3
Stage of disease
I 40 37.7
II 42 39.6
III 22 20.7
IV 2 1.9
Nottingham histologic grade
G1 16 15.1
G2 34 32.1
G3 56 52.8
Histological type
NOS 93 87.7
Lobular 11 10.4
Other 2 1.9
Molecular subtype
Luminal A 33 31.1
Luminal B 14 13.2
Luminal B/HER2+ 12 11.3
HER2+ non-luminal 20 18.9
Triple negative 27 25.5
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p < 0.015), higher Treg percentage (11.2 ± 4.2 vs. 9.4 ± 3.7,
p < 0.020), and Treg/Th2 cell percentage ratio at the invasion
front (0.25 ± 0.13 vs. 0.21 ± 0.18, p < 0.030) in comparison
with metastasis-free cases. After stratification into luminal
and non-luminal cancers, we noted that a higher intratumoral
CTL/Treg number ratio was associated with regional lymph
Fig. 2 The significant differences in T cell subpopulation infiltrates of
primary breast cancer tissue with reference to molecular subtypes. Lum
A, luminal A; Lum B, luminal B/ HER2−; Lum B/HER2+, luminal
B/HER2+; HER2+, HER2+ non-luminal; TNBC, triple-negative sub-
type. Central point is the arithmetic mean, box is the arithmetic mean ±
standard error, and whisker is the arithmetic mean ± standard deviation.
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node metastases (p < 0.035) in the latter group. For luminal
tumors, there was a tendency toward higher Treg/Th2 cell
percentage ratio at the edge of tumors of positive nodal status
(p = 0.051; Fig. 3).
In terms of tumor histologic grade, we observed that tumor-
associated infiltrates differed in numbers of CTLs in
intratumoral area and tumor edge (p < 0.002 and p < 0.001, re-
spectively) as well as in both populations of Tregs (intratumoral
p < 0.003, invasive margin p < 0.001) and TIL abundance
(p < 0.001) as well as in the percentage of Treg lymphocytes
(p < 0.008) and the Treg/Th2 cell percentage ratio at the invasion
front (p < 0.035), with their increased levels in G3 as compared
to G1 tumors. Additionally, for Treg numbers, both in
intratumoral and invasive margin location, CTL numbers at
the tumor edge, and TIL infiltrates, significantly higher levels
were noted in G3 than in G2 cancers (p < 0.040, p < 0.006,
p < 0.001, and p < 0.001, respectively; Tables 3 and 4).
As far as the histologic type was concerned, NOS cancers
were characterized by more abundant TILs (30.3 ± 20.3 vs.
13.1 ± 9.3, p < 0.003), more numerous CTLs of invasive mar-
gin (793.1 ± 461.7 vs. 380.0 ± 286.1, p < 0.003) and Tregs at
the tumor edge (256.4 ± 180.8 vs. 101.0 ± 96.2, p < 0.002),
and a higher Treg percentage at invasion front (10.6 ± 4.1 vs.
8.6 ± 3.9, p < 0.050) as well as decreased intraepithelial CTL/
Treg number ratio (3.27 ± 2.43 vs. 7.09 ± 3.86, p < 0.001) as
compared with CLI lesions.
The tumor tissue excisions obtained from stage I patients
were related to a significantly lower TIL level (19.7 ± 15.1 vs.
36.1 ± 22.5, p < 0.001), lower counts of CTLs (596.8 ± 449.8
vs. 864.3 ± 472.1, p < 0.015), and Tregs at invasive margin
(176.3 ± 152.8 vs. 288.7 ± 206.7, p < 0.015) as well as a lower
Treg percentage (9.0 ± 4.1 vs. 10.5 ± 2.8, p < 0.045) and Treg/
Th2 cell percentage ratio at the tumor edge (0.20 ± 0.20 vs.
0.24 ± 0.12, p < 0.035) in comparison with stage II cancers;
for the two latter parameters, such a difference was also ob-
served between stage I and stage III/IV cancers (stage III/IV:
Treg percentage − 12.3 ± 5.0, p < 0.009, Treg/Th2 cell per-
centage ratio − 0.26 ± 0.12, p < 0.020).
Discussion
CTLs are commonly considered as a part of cancer immune
surveillance. Some research into breast cancer-linked CTLs
revealed their lytic and proapoptotic activity [18] as well as
a memory phenotype in the majority of this cell population,
particularly when high-grade lesions were concerned [19].
Tsang et al. [20] observed that CD8+ and FOXP3+ expres-
sions were mutually exclusive in double immunohistochemi-
cal staining of breast cancer microenvironment. On the con-
trary, the existence of fractions of CTLs that express FOXP3
secrete immunosuppressive interleukin (IL)-10 [21] and co-
express molecules associated with anergy, exhaustion, orTa
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unresponsiveness in tumor-infiltrating lymphocytes [22] was
reported.
The data on associations between lymphocytic infiltrate
and breast cancer molecular subtype are inconclusive. In line
with our study, some authors reported that increased CTL
counts were associated with ER and PR negativity, HER2
overexpression [23–25], and higher Ki67 level [25, 26] in
breast cancer, while the results from other publications ques-
tion these findings [20, 26, 27]. Liu et al. hypothesized that the
location of immune infiltrates (intraepithelial or peritumoral)
may influence activation of its cells, as cell populations within
a tumor are dispersed and their interactions are impeded [23].
In the Miyan et al. study, a significantly increased number of
CTLs was observed at the invasive margin of basal-like and
luminal B/HER2+, with their lowest counts in luminal A le-
sions [25]; however, the authors applied St Gallen 2013 mo-
lecular subtype classification in their research. Tsang et al.
suggested that the mechanism of intratumoral recruitment
and survival of lymphocytes may differ between subtypes,
and that in HER2-positive tumors, CTL migration is preferred
over Treg influx [20]. Our observation of high CTL counts in
HER2+ non-luminal and triple-negative phenotypes was
made for a population of these cells located at tumor edge,
exclusively. On the other hand, the percentages of CTLs in
tumor-associated infiltrates at invasive margin did not differ
between subtypes. Therefore, the increased numbers of CTLs
may reflect more abundant TILs noted in these breast cancer
subtypes rather than a shift in immune response toward more
potent cell killing. A favorable prognostic value of high levels
of breast cancer-related CTLs was attributed to ER-negative as
well as ER+/HER2+ phenotypes [28]. Moreover, high FAS
protein expression in ER-negative cancers was proposed to be
one of the contributing factors to beneficial impact of CTL on
patient survival. Of note, their adverse effect on ER-positive
FAS-high patient outcome indicated different functions of
tumor-infiltrating CTLs with respect to breast cancer subtypes
[29].
Literature data on relationships between CTLs and other
prognostic factors in invasive breast cancer are also ambigu-
ous. Some authors [14, 19, 23–25], but not all [23, 27, 30],
report higher CTL counts in tumors of higher histological
grade and size, which is in line with our findings. We noted
that relationships between more numerous CTL infiltrates and
higher grades concerned both intraepithelial area and tumor
edge, while tumors of greater diameter were characterized
only by a more abundant intraepithelial population. After
stratification, the latter finding remained significant for lumi-
nal lesions, exclusively. Regarding lymph node metastases,
higher counts [26, 27, 31] as well as a higher frequency of
CTLs [19] were observed in primary tumors with nodal
spread, but such association was not observed by other groups
[23, 32]. In our study, the CTL infiltrates did not differ accord-
ing to nodal status.
FOXP3 is a transcription marker expressed in a vast ma-
jority of breast cancer-infiltrating Tregs [33]. Similar to CTLs,
Tregs were observed to accumulate in breast tumor and its
immediate milieu, in comparison with normal tissue.
Moreover, tumor-infiltrating Tregs were more frequently char-
acterized by activated, strongly immunosuppressive but
exhausted phenotype, which may correspond with immune
tolerance [22]. As far as the breast cancer intrinsic subtypes
were concerned, the most numerous regulatory Tcell infiltrate
is frequently associated with either TNBC or HER2+ non-
luminal phenotype of tumors, while the lowest Treg numbers
are observed in luminal A lesions [23, 25, 34], which is in
accordance with our results. Moreover, the stronger Treg in-
filtrate of TNBC concerns both the surrounding stroma and
tumor center. Such findings indicated associations between
tumor biological features and immunological response in in-
vasive breast cancers [25] as well as more immunosuppressive
Fig. 3 The significant differences in T cell subpopulation infiltrate of
primary breast cancer tissue with reference to nodal status, after
stratification upon breast cancer phenotype. Central point is the
arithmetic mean, box is the arithmetic mean ± 2*standard error, and
whisker is the arithmetic mean ± 0.95*standard deviation.
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microenvironment of clinically aggressive subtypes [23].
Moreover, the increased proportion of Tregs in a lymphocytic
milieu [35], as well as their higher quantities, was noted in
TNBC and hormone receptor (HR)-negative and HER2-
overexpressed breast tumors [23, 34], which supports our re-
sults. We also observed slight correlations between Treg per-
centage in immune cell infiltrates of invasive edge and either a
drop of PR or an increase in Ki67 expression that suggest a
shift toward a more immunotolerant milieu in PR-negative or
intensively proliferating breast cancers. More abundant Tregs
were found in the center of ER-positive and in the peritumoral
area of ER−/HER2+ cancers, while a lower number of cells
infiltrated the intratumoral site of ER−/HER2+ tumors in
Tsang et al. research [20]. Some authors did not observe any
differences in Treg infiltrates regarding breast cancer intrinsic
subtypes [36]. In ER-negative tumors, more intensive Treg
infiltration was associated with better disease-free survival
[33]. Similar to CTLs, higher levels of Tregs were often ob-
served in high-grade cancers [14, 23, 35], but their relation-
ship with tumor size and nodal status is controversial [22, 23,
26, 34]. We found increased Treg numbers and percentages in
luminal breast tumors of greater size, as well as a higher pro-
portion of Tregs in the microenvironment of node-positive
invasive tumors, that suggests a regulatory bias in TILs of
more advanced cancers.
The ratio of CTL to Treg numbers is regarded as an indi-
cator of cytotoxicity. A higher CD8+/FOXP3+ ratio was ob-
served by Liu et al. in the peritumoral area of non-luminal
breast cancers and indicated greater cytolytic potential of the
lymphocytic milieu surrounding these tumors [23]. It was
postulated that the change of this parameter is rather due to
Treg reduction than CTL recruitment [14]. Complementary
FOXP3+/CD8+ cell ratio was suggested to reflect an immune
evasion of a tumor, with its higher values in tumor center as
compared with the peritumoral area. In breast tumor, it was
associated with ER negativity, higher proliferation rate, and
high histological grade, but not with tumor size or nodal in-
volvement [25]. In our study, increased intraepithelial CTL/
Treg number ratio was associated with lobular histology and
metastatic disease of non-luminal cancers. Thus, we hypothe-
size that, for breast tumors of non-luminal phenotype, their
spread is associated with cytotoxicity failure.
Information on tumor-associated Th2 cells in breast cancer
is scarce. Th2 was reported as a predominant population of T
helper cells in a mouse model of luminal breast cancer; their
lower counts in the tumor milieu were associated with de-
creased pulmonary metastasis by Zhang et al. [37].
Moreover, higher levels of Th2 cytokines—IL-10 [14] and
IL-5 [3]—were related to the lack of pathologic complete
response after chemotherapy and worse survival in breast can-
cer patients, respectively. In our study, tumor-associated Th2
cells showed a slight correlation with HR. On the contrary, the
expression of genes related to Th2 signaling was more
prominent in basal cancers by Kristensen et al. [38]. Ghirelli
et al. showed that cytokines secreted by breast cancer tissue
resulted in regulatory Th2 bias of tumor-related immunity,
which supposedly was GATA3 independent [39]. To assess
immunoregulatory and suppressive potential of immune infil-
trates, we evaluated the Treg/Th2 cell percentage ratio. Its
high value was associated with adverse prognostic indicators:
HER2+ non-luminal subtype, decrease in HR expression, in-
creasing proliferation rate, and higher grade as well as greater
tumor size and positive lymph node status, particularly in
luminal cancers. In addition, the higher percentage ratio of
CTLs to Th2 at invasion front modestly correlated with HR
expression. Thus, we hypothesize that the bias of immunosup-
pressive microenvironment toward regulatory function is as-
sociated with clinically more aggressive breast cancers.
Our recent research studies aimed at evaluation of tumor
microenvironment in primary invasive breast cancer have
shown associations between higher quantities of mast cells
and beneficial prognostic indicators [40] and relationships be-
tween T cell, B cell, and NK cell infiltrates and adverse clinical
factors [41]. These findings induced us to presently investigate
infiltrates of several T cell subpopulations in this disease. In
conclusion, we observed that T cell infiltrates of primary inva-
sive breast tumors differ in numbers and percentages of its
individual populations regarding cancer molecular features
and prognostic markers. Moreover, the relationships between
lymphocytic composition and pTor nodal status vary according
to cancer phenotype, suggesting that distinct mechanisms gov-
ern cancer progression in luminal and non-luminal lesions. As
more numerous T cell subpopulations in breast cancer tissue
may result from higher TIL levels, we additionally evaluated
percentages of analyzed cells in tumor-surrounding infiltrates
that should be resistant to the number of TILs. Thus, further
investigation is needed to elucidate function of immune infil-
trates in breast cancers of different molecular subtypes.
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